"A key challenge we have – at Gilead but also as an industry – is how to expedite access to medicines for patients in Canada."
In Conversation
"For the first time, after many years, we have a government commitment to increase the budget allocated to research by 20 percent"
"Through Pascal Soriot’s global leadership, AstraZeneca has a robust and exciting global pipeline that we can leverage at the local level."
"Ipsen Canada has had a great start. We are somewhat of a poster child for the Ontario government now when it comes to attracting more foreign…
"The idea is to provide an integrated healthcare provision system that allows the patient to move more fluidly from home to hospital and back. The goal…
"When we are talking about addressing issues within the wider health systems, I believe all stakeholders need to be involved, and that includes industry."
Therapure President and CEO, Nick Green, speaks about the environment for contract development and manufacturing in Canada and the integrated services that Therapure can offer its…
The CEO of DelMar Pharmaceuticals discusses British Columbia’s competitive strengths in the biotechnology space, and demonstrates how his company’s therapy for glioblastoma will change the way…
John Soloninka, President & CEO of HTX, talks about his vast experience in the pharmaceutical and healthcare sector, why he feels there is much room for…
Pierre Montanaro, President and CEO of Pharmetics, discusses the history of his company’s work in the private label business and future plans to expand into a…
David Goodman, CEO of Pharmascience, describes the importance of balancing innovation with low cost products in Canada and outlines his company’s strategy for growth domestically and…
John Soloninka, President & CEO of HTX, talks about his vast experience in the pharmaceutical and healthcare sector, why he feels there is much room for…
